期刊
INFECTION AND IMMUNITY
卷 75, 期 3, 页码 1089-1098出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.01184-06
关键词
-
资金
- NHLBI NIH HHS [R01 HL070946, R21 HL079393, R01-HL070946, R21-HL079393] Funding Source: Medline
- NIAID NIH HHS [K22 AI065828, R01-AI49577, R01 AI049577] Funding Source: Medline
A number of bacterial pathogens utilize the type III secretion pathway to deliver effector proteins directly into the host cell cytoplasm. Certain strains of Pseudomonas aeruginosa associated with acute infections express a potent cytotoxin, exoenzyme U (ExoU), that is delivered via the type III secretion pathway directly into contacting host cells. Once inside the mammalian cell, ExoU rapidly lyses the intoxicated cells via its phospholipase A(2) (PLA(2)) activity. A high-throughput cell-based assay was developed to screen libraries of compounds for those capable of protecting cells against the cytotoxic effects of ExoU. A number of compounds were identified in this screen, including one group that blocks the intracellular activity of ExoU. In addition, these compounds specifically inhibited the PLA(2) activity of ExoU in vitro, whereas eukaryotic secreted PLA(2) and cytosolic PIA, were not inhibited. This novel inhibitor of ExoU-specific PLA(2) activity, named pseudolipasin A, may provide a new lead for virulence factor-based therapeutic design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据